These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17440699)

  • 1. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
    Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R
    Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T; Mouridsen K; Maxwell RJ; Stødkilde-Jørgensen H; Østergaard L; Horsman MR
    Acta Oncol; 2008; 47(7):1265-70. PubMed ID: 18661437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
    Drees R; Hünigen H; Wagner S; Schnorr J; Plendl J; Taupitz M
    Vet Comp Oncol; 2008 Sep; 6(3):151-61. PubMed ID: 19178675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
    Medved M; Karczmar G; Yang C; Dignam J; Gajewski TF; Kindler H; Vokes E; MacEneany P; Mitchell MT; Stadler WM
    J Magn Reson Imaging; 2004 Jul; 20(1):122-8. PubMed ID: 15221817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents.
    Marzola P; Ramponi S; Nicolato E; Lovati E; Sandri M; Calderan L; Crescimanno C; Merigo F; Sbarbati A; Grotti A; Vultaggio S; Cavagna F; Lorusso V; Osculati F
    Invest Radiol; 2005 Jul; 40(7):421-9. PubMed ID: 15973133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Gd-DTPA enhanced MRI as a surrogate marker of angiogenesis in tissue-engineered bladder constructs: a feasibility study in rabbits.
    Cheng HL; Chen J; Babyn PS; Farhat WA
    J Magn Reson Imaging; 2005 Apr; 21(4):415-23. PubMed ID: 15778952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
    de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
    Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
    Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
    Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of early response to radiotherapy of uterine carcinoma with dynamic contrast-enhanced MR imaging using pixel analysis of MR perfusion imaging.
    Takayama Y; Ohno T; Kishimoto R; Kato S; Yoneyama R; Kandatsu S; Tsujii H; Obata T
    Magn Reson Imaging; 2009 Apr; 27(3):370-6. PubMed ID: 18768283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted magnetic resonance imaging with intraperitoneal and intravenous streptavidin (SA)-DTPA-Gd: a comparative study in tumor-bearing nude mice.
    Ye J; Xu YK; Liu X; Lü GS
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):139-43. PubMed ID: 16503514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.